NASDAQ:BLUE has dropped significantly from its $150 highs to its current price level around $1. I think BLUE is forming a dead cat bounce in the green support zone, and I can see a short-term swing up to the yellow trendline. The price has already rebounded quite a bit, I would look for an entry around the green support zone between $0.87 and $1.02. I can see...
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene...
BLUE a week ago had a bull run to gain 90% in 5 days and then reversed into a standard
Fibonacci retracement on the 30-minute chart, then in consolidation for a day or two getting
support from the mean anchored VWAP. The last trading day was a quick rise with momentum
in a bull flag. Earnings are coming. I will take another long trade on BLU into earnings....
BLUE is currently trading above its 50-day and 200-day simple moving averages (SMA), indicating a bullish trend. However, the 50-day SMA is below the 200-day SMA, forming a death cross pattern, which is a bearish signal.
The 20-day exponential moving average (EMA) is also above the current price, acting as a resistance level. A break above the 20-day EMA could...
BLUE
Blue Bio
Covered Call expiring 9/15/2023
price 3.46
moneyness -1.16%
bid 0.40
net debit 3.06
break even 13.07%
volume 2
open interest 108
delta -0.56333
I.V. 122.47%
potential return 14.4%
annual return 169.3%
Sniper Stochastics shows a cross of white line (55 %K), and the blue and red lines are below.
I am selecting the options expiring 9/15/2023.
There...
On Balance Volume has been (bullishly) diverging from price since May indicating that "smart money" has likely been accumulating.
ADX is a level that implies a trend and D+ crossing D- indicates that it is bullish.
Recently we see price test the .236 Fibonacci level on higher than average daily volume days after gapping up and possibly changing trend (higher...
Bluebird bio (BLUE) is a biotech company focused on developing and commercializing gene and cell therapies to treat genetic diseases. Lead asset LentiGlobin (Zynteglo) is approved in US and Europe for the treatment of transfusion-dependent thalassemia. Bluebird's LentiGlobin (lovo-cel) is also in pre-registrational stage for sickle cell disease.
Bluebird is also...
BlueBird Bio / BLUE had an earnigns report this past week showing earnings for the firat time
but revenue was far below analyst's projections. Price has appreciated 40% in the 4 weeks
since earnings which is about 500% annualized. GO BLUE.
On the daily chart, price was above VWAP and consolidating much of last fall then dropped
this YTD until the earnings...
$BLUE has been in down trend just recently formed a potential rounding bottom reversal. If price can break through $7.50 then $8 it can head to $11.75 area.
$7.50 is an important resistance area and breaking through that would require quite a push from the bulls.
Target 1 - $7.50
Target 2 - $8.00
Target 3 - $11.00
Risk - fail to get above $7.50. Retreat to $5...
NASDAQ:BLUE Just Start to develop BULL trend after price broke up VERA moving average first time since nov 2021, next LVL 12.50 target price enjoy
@GTINDICATORS
looking to short from C wave.. In addition I see bearish price action set up from the 4th wave down to the 5th wave . The AD is also confirming a bearish rounding top and inverted cup/handle bearish trade set up
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent -thalassemia; LentiGlobin for the treatment of sickle cell disease; and...
bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees,...
